• Login
    View Item 
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2015 RD&E publications
    • View Item
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2015 RD&E publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Successful maintenance on sulfonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort

    Thumbnail
    URI
    http://hdl.handle.net/11287/593964
    Author
    Bacon, S.
    Kyithar, M. P.
    Rizvi, S. R.
    Donnelly, E.
    McCarthy, A.
    Burke, M.
    Colclough, Kevin
    Ellard, Sian
    Byrne, M. M.
    Date
    2015-11-17
    Journal
    Diabetic medicine : a journal of the British Diabetic Association
    Type
    Journal Article
    Publisher
    Wiley
    DOI
    10.1111/dme.12992
    Metadata
    Show full item record
    Abstract
    AIMS: HNF1A gene mutations are the most common cause of maturity-onset diabetes of the young (MODY) in the UK. Persons with HNF1A-MODY display sensitivity to sulfonylurea therapy; however, the long-term efficacy is not established. There is limited literature as to the prevalence of micro- and macrovascular complications in this unique cohort. The aim of this study was to determine the natural progression and clinical management of HNF1A-MODY diabetes in a dedicated MODY clinic. METHODS: Sixty patients with HNF1A-MODY and a cohort of 60 BMI-, age-, ethnicity- and diabetes duration-matched patients with Type 1 diabetes mellitus participated in the study. All patients were phenotyped in detail. Clinical follow-up of the HNF1A-MODY cohort occurred on a bi-annual basis. RESULTS: Following a genetic diagnosis of MODY, the majority of the cohort treated with sulfonylurea therapy remained insulin independent at 84-month follow-up (80%). The HbA1c in the HNF1A-MODY group treated with sulfonylurea therapy alone improved significantly over the study period [from 49 (44-63) mmol/mol, 6.6 (6.2-7.9)% to 41 (31-50) mmol/mol, 5.9 (5-6.7)%; P = 0.003]. The rate of retinopathy was significantly lower than that noted in the Type 1 diabetes mellitus group (13.6 vs. 50%; P = 0.0001).There was also a lower rate of microalbuminuria and cardiovascular disease in the HNF1A-MODY group compared with the Type 1 diabetes mellitus group. CONCLUSIONS: This study demonstrates that the majority of patients with HNF1A-MODY can be maintained successfully on sulfonylurea therapy with good glycaemic control. We note a significantly lower rate of micro- and macrovascular complications than reported previously. The use of appropriate therapy at early stages of the disorder may decrease the incidence of complications.
    Citation
    Diabet Med. 2016 33(7) 976-84
    Publisher URL
    http://dx.doi.org/10.1111/dme.12992
    Collections
    • 2015 RD&E publications
    • Molecular Genetics

    Browse

    All of RD&E Research RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2021  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV